Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Definium Therapeutics, Inc. (DFTX) is a clinical-stage biopharmaceutical company developing a rapid-acting, single dose LSD-based therapy for major depressive disorder and generalized anxiety disorder, administered in a monitored clinical setting. We own it...
— Chad Meade
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Definium Therapeutics, Inc.
No other institutional pitches found for this ticker yet.
More institutional theses from Meridian Small Cap Growth Fund
Hinge Health's stock advanced following an earnings beat, an upward revision to full-year guidance, and accelerating client bookings. The company also...
Tandem Diabetes Care is an automated insulin delivery technology provider poised for long-term growth in both Type 1 and Type 2 diabetes markets. Although near-term U.S....
International Money Express is a remittance and money transfer provider whose shares fell after a strategic review concluded without a sale, disappointing short-term investors. Near-term margins face...